- Home
- AGIO vs BBAR Comparison
AGIO vs BBAR Comparison
Compare AGIO & BBAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- BBAR
- Stock Information
- Founded
- AGIO 2007
- BBAR 1886
- Country
- AGIO United States
- BBAR Argentina
- Employees
- AGIO N/A
- BBAR N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- BBAR Commercial Banks
- Sector
- AGIO Health Care
- BBAR Finance
- Exchange
- AGIO Nasdaq
- BBAR Nasdaq
- Market Cap
- AGIO 2.1B
- BBAR 1.8B
- IPO Year
- AGIO 2013
- BBAR N/A
- Fundamental
- Price
- AGIO $36.39
- BBAR $8.99
- Analyst Decision
- AGIO Buy
- BBAR Buy
- Analyst Count
- AGIO 6
- BBAR 1
- Target Price
- AGIO $57.00
- BBAR $27.00
- AVG Volume (30 Days)
- AGIO 771.2K
- BBAR 1.1M
- Earning Date
- AGIO 10-30-2025
- BBAR 08-20-2025
- Dividend Yield
- AGIO N/A
- BBAR 0.25%
- EPS Growth
- AGIO N/A
- BBAR N/A
- EPS
- AGIO 11.13
- BBAR 0.38
- Revenue
- AGIO $40,875,000.00
- BBAR $1,945,235,030.00
- Revenue This Year
- AGIO $28.19
- BBAR N/A
- Revenue Next Year
- AGIO $152.14
- BBAR $23.38
- P/E Ratio
- AGIO $3.27
- BBAR $8.04
- Revenue Growth
- AGIO 30.57
- BBAR N/A
- 52 Week Low
- AGIO $23.42
- BBAR $8.69
- 52 Week High
- AGIO $62.58
- BBAR $25.01
- Technical
- Relative Strength Index (RSI)
- AGIO 51.16
- BBAR 23.80
- Support Level
- AGIO N/A
- BBAR $8.68
- Resistance Level
- AGIO $37.18
- BBAR $9.91
- Average True Range (ATR)
- AGIO 1.43
- BBAR 0.60
- MACD
- AGIO -1.50
- BBAR -0.25
- Stochastic Oscillator
- AGIO 88.53
- BBAR 7.21
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About BBAR Banco BBVA Argentina S.A. ADS
Banco BBVA Argentina SA is a banking services provider in Argentina. It provides financial assistance to large corporations, small and medium-sized companies, as well as individuals. It bank provides services through retail, corporate, investment banking, and Small and medium-sized companies divisions. Through the retail banking segment, it provides banking products and services to individuals, corporate banking deals with services to corporates, and the small and medium-sized companies segment focuses on foreign trade, agricultural business, and digital products.